NEW YORK (GenomeWeb) – Cancer informatics and precision medicine firm Tempus said today that it has raised $110 million in a Series E financing round.
Participants in the round included Baillie Gifford, funds and accounts managed by T. Rowe Price, Revolution Growth, New Enterprise Associates, and other existing investors.
Tempus, based in Chicago, said that it will use the additional funds to grow operations and expand into new therapeutic areas and geographies.
With the latest cash influx, Tempus has now raised $320 million to date, including an $80 million Series D round in March and a $70 million Series C round last year.
Tempus has built a library of molecular and clinical data alongside an operating system to make the data useful. The company uses machine learning, next-generation sequencing, and AI-assisted image recognition to enable scientific discovery and help physicians make real-time decisions to guide treatment of their patients.
The company has partnerships with the American Society of Clinical Oncologists, as well as several academic medical centers and National Cancer Institute-designated cancer centers, hospital networks, and community physicians in the US.
In January it announced it had formed precision cancer medicine partnerships with the New York University School of Medicine and Vanderbilt-Ingram Cancer Center.